A First in Human Phase I Study of INVAC-1 as a Single Agent in Patients With Advanced Cancer

Trial Profile

A First in Human Phase I Study of INVAC-1 as a Single Agent in Patients With Advanced Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs HTERT DNA vaccine Invectys (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Invectys
  • Most Recent Events

    • 06 Jun 2017 Results (n=20) of clinical and pharmacodynamic assessment of INVAC-1 as a single agent in patients with refractory/progressive advanced solid tumors, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 01 Mar 2017 Planned number of patients changed from 18 to 26.
    • 01 Mar 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top